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Shuang Huang, Ph.D. Angiogenesis is essential for the growth and metastasis of solid tumors including breast cancer. In vitro and in vivo experimental models clearly demonstrate that suppressing angiogenesis leads tumor suppression. The overall goal of this proposal is to develop an adenovirus-based gene therapy approach for suppressing angiogenesis. In first year of the funding period, we have successfully constructed a human endothelial cell-targeted adenovirus gene delivery vector. In this second year of funding period, we successfully constructed endothelial cell-targeted adenoviral vector containing therapeutic genes including soluble VEGF receptor (sFlk and sFlt) and dominant negative angiogenesis-essential signaling molecules including Raf-1 and PI-3K. These vectors were found to significantly inhibit VEGF-induced human endothelial cell migration and in vitro angiogenesis. In the last year of the funding, we have focused on our effort to determine whether the endothelial cell-targeted adenoviral vector can be used to deliver anti-angiogenesis agents to block angiogenesis and tumor development in animal models. Our studies demonstrate that our approach can sufficiently inhibit both angiogenesis and breast tumor development. We believe that our endothelial cell target adenoviral vector provide a useful means for specifically delivering therapeutic agents to angiogenic tumors. Animals receiving Ad/sFlk, Ad/PI-3K(-) and combination of both Ad vectors displayed the reduction in tumor mass of 62%, 77%, and 89% respectively comparing to animals receiving the control virus (Fig.1) . These results suggest that delivering anti-angiogenic genes to the angiogenic tumors is capable of suppressing breast cancer development.
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
To determine the effect of endothelial cell-targeted adenovirus-delivered sFlk and PI-3K(-) on the survival of tumor-bearing nude mice, we monitored the remaining six 
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In contrast, animals receiving Za IAd/sFlk and Ad/PI-3K(-) lived 15 average of 13.4 and 13.8 weeks )respectively (Fig.2) . In six "animals receiving the 5.
combination of both Ad vectors, we have one animals 0-,-are still alive after 30 weeks. The five deceased mice lived average of 20.8 weeks (Fig.2) . cancer-bearing animal survival.
2. Human/nude mouse model. average mass of 464mg (Fig.3 ).
administrated to animals via tail veins. After 6 weeks, animals were sacrificed, grafts removed and analyzed for the presence of tumo rs.
In contrast, mice received Note. Two mice receiving combination of Ad/ sFIk and Ad/PI-3K (-) did not grow tumors on the grafted skin.
Ad.sFlk and Ad.PI-3K(-) had tumors at the average mass of 264 and 171 mg respectively 6
